Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Athira Pharma, Inc. (ATHA) Common Stock

June 18, 2021 1:05 PM EDT | Source: Wolf Popper LLP

New York, New York--(Newsfile Corp. - June 18, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) common stock.

Athira is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira's lead drug candidate is ATH-1017 which is used to treat Alzheimer's and Parkinson's dementia. Athira conducted an initial public offering of its common stock on September 17, 2020.

On June 17, 2020, at approximately 5:00p.m. EST, after trading markets had closed for the day Athira issued a press release that disclosed that the Board of Directors of Athira had determined "to place Leen Kawas, PhD, President and Chief Executive Officer of Athira, on temporary leave pending a review of actions stemming from doctoral research Dr. Kawas conducted while at Washington State University." Athira also announced that its Board had formed an independent special committee to review this matter.

On June 18, 2021, Athira common stock opened at $10.47 per share, a decline of $7.77, or 42.6%, from its closing price on June 17, 2021.

For more information, Athira investors with trading losses of over $50,000 should contact Joshua Ruthizer at (212) 451-9668 or at jruthizer@wolfpopper.com.

Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm's website at www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP
Joshua Ruthizer
845 Third Avenue
New York, NY 10022
Tel.: (212) 451-9668
Email: jruthizer@wolfpopper.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88037

info